Citius Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended June 30, 2018; filed August 14, 2018. Citius is a development-stage specialty pharmaceutical company with no revenue to date. Its key programs include Phase 3 Mino-Lok, an antibiotic lock treatment for catheter-related bloodstream infections, and Phase 2b Hydro-Lido.
Financial performance and position
| Metric | Three months ended June 30, 2018 | Nine months ended June 30, 2018 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $778,856 | $4,825,230 |
| General and administrative expense | $1,114,740 | $4,673,405 |
| Total operating expenses | $2,017,994 | $10,127,720 |
| Operating loss | $2,017,994 | $10,127,720 |
| Net loss | $2,021,894 | $9,689,710 |
| Basic and diluted loss per share | $0.19 | $0.99 |
| Net cash used in operating activities | Not presented for quarter | $8,813,550 |
At June 30, cash and cash equivalents were $2,761,805, working capital was $644,529, and total current liabilities were $2,190,404. Related-party notes payable were $172,970, with $54,006 of accrued related-party interest. Total assets were $23,825,614, including $19.4 million of in-process research and development and $1.6 million of goodwill. The filing reports no revenue, so revenue margins are not meaningful. No income tax benefit was recorded.
Changes versus prior comparable periods
- For the quarter, net loss narrowed to $2.02 million from $2.42 million. R&D expense increased by $588,208, primarily reflecting the Mino-Lok Phase 3 trial; lower G&A, stock compensation, and derivative-warrant revaluation loss more than offset that increase.
- For the nine months, net loss increased to $9.69 million from $7.34 million. R&D expense rose $2.36 million, principally due to Mino-Lok development. G&A increased $359,702, while stock-based compensation declined $179,271.
- Nine-month results included a $450,000 gain from reversing an accrued R&D liability that the company said would not be paid. The prior-year period included a $308,878 gain on derivative-warrant revaluation; no derivative warrant liability remained at June 30, 2018.
- Cash fell $442,303 during the nine months, as $8.37 million of financing cash inflows largely offset operating cash use. The company raised net proceeds of $5.48 million in a December 2017 registered direct/private placement and $1.76 million in a March 2018 offering, and received $1.13 million from warrant exercises.
Outlook, risks, and other notable items
- Going concern and funding: The filing states that the company had incurred recurring losses, had no operating revenue, and faced substantial doubt about its ability to continue as a going concern. Management planned additional equity financing and related-party borrowing; success, timing, and acceptable terms were not assured.
- Subsequent offering: On August 13, 2018, the company completed an underwritten offering of common-stock units and pre-funded units, each paired with warrants. It reported approximately $8.8 million of net proceeds. The filing also describes the transaction as a $10.0 million offering and says management believed available cash would fund anticipated requirements into the second half of 2019.
- Development outlook: Management expected R&D expense to increase as it continued the Mino-Lok Phase 3 trial and said it was seeking capital to fund development. Clinical success, regulatory approval, commercialization, and future financing remain uncertain.
- Dilution and commitments: At June 30, 4,479,465 warrants were outstanding, along with stock options and other equity awards. The NAT license for Mino-Lok includes annual maintenance fees, sales-based royalties, up to $1.39 million in milestone payments, and sublicense-related payments.
- Controls: Management concluded disclosure controls were ineffective and identified material weaknesses: lack of documented policies and procedures, reliance on consultants for financial reporting, and ineffective segregation of duties due to limited staff.
- The filing reports no legal proceedings, no off-balance-sheet arrangements, and no change in risk factors from the prior Form 10-K.
Important facts for investors to verify
- Cash runway and operating burn after the August 2018 offering, including whether management’s second-half-2019 funding estimate remains supportable.
- Offering proceeds and terms: the filing cites both a $10.0 million offering and approximately $8.8 million in net proceeds; confirm gross proceeds, fees, and securities issued.
- Mino-Lok Phase 3 progress, costs, enrollment, timing, and any subsequent clinical or regulatory updates; likewise, confirm Hydro-Lido development status.
- Potential dilution from outstanding warrants, options, and the August offering securities, as well as related-party debt and financing arrangements.
- Progress in addressing the disclosed material weaknesses and any subsequent changes in internal controls.